Pleural Effusion

The first step in evaluating a pleural effusion is determining whether it is a transudate or an exudate. This distinction narrows the differential significantly and guides further workup.

Transudates result from increased hydrostatic pressure or decreased oncotic pressure — the pleural membranes are normal, and fluid accumulates because of systemic forces. The most common causes are heart failure (most common overall), cirrhosis with hepatic hydrothorax, and nephrotic syndrome. Transudates do not require extensive pleural fluid analysis beyond confirming the diagnosis — the workup focuses on the underlying systemic condition.

Exudates result from inflammation, infection, or malignancy involving the pleural membranes — the membranes are abnormal and are producing or failing to reabsorb fluid. The most common causes are pneumonia (parapneumonic effusion), malignancy, and pulmonary embolism. Exudates require thoracentesis with detailed fluid analysis to identify the cause.

The clinical context often suggests the category before thoracentesis: bilateral effusions in a patient with heart failure, elevated JVD, and peripheral edema are almost certainly transudates. A unilateral effusion in a patient with fever and pneumonia is almost certainly an exudate. Thoracentesis is most valuable when the clinical picture is ambiguous or atypical.

Light's criteria classify an effusion as exudative if any one of three criteria is met: (1) pleural fluid protein / serum protein ratio above 0.5, (2) pleural fluid LDH / serum LDH ratio above 0.6, or (3) pleural fluid LDH above two-thirds the upper limit of normal serum LDH. If none of the criteria are met, the effusion is a transudate.

Light's criteria have a sensitivity of approximately 98% for exudates — they rarely misclassify a true exudate as a transudate. However, the specificity is lower — approximately 25% of transudates are misclassified as exudates, particularly in patients with heart failure who have been treated with diuretics. Diuresis concentrates the pleural fluid, raising the protein and LDH ratios into the exudative range even though the underlying mechanism is hydrostatic.

When Light's criteria classify an effusion as exudative in a patient with a strong clinical suspicion for heart failure, the serum-pleural albumin gradient can help resolve the discrepancy. A serum-pleural albumin gradient above 1.2 g/dL (serum albumin minus pleural albumin) suggests a transudate despite exudative Light's criteria. This is the most useful correction for diuretic-treated heart failure effusions.

Ionized calcium, cholesterol, and other markers have been proposed as adjuncts, but the serum-pleural albumin gradient is the most clinically validated correction for the diuresis artifact.

Thoracentesis is indicated when: the cause of the effusion is unknown, the effusion is large enough to cause symptoms, or there is clinical concern for infection (empyema) or malignancy. It is not required for bilateral effusions in a patient with a clear clinical diagnosis of heart failure, unless the effusions are asymmetric, the patient is febrile, or the clinical picture is atypical.

Standard pleural fluid analysis includes: appearance (clear, cloudy, bloody, purulent), protein, LDH, glucose, pH, cell count with differential, Gram stain, and culture. Additional tests are ordered based on clinical suspicion: cytology (malignancy), adenosine deaminase (tuberculosis), triglycerides (chylothorax), amylase (esophageal rupture, pancreatitis), and hematocrit (hemothorax). Serum protein and LDH must be drawn simultaneously for Light's criteria calculation.

Pleural fluid appearance provides immediate diagnostic clues: bloody fluid suggests malignancy, trauma, or pulmonary infarction; milky fluid suggests chylothorax; turbid fluid suggests infection or high cell count; frank pus confirms empyema. A very low glucose (below 30 mg/dL) suggests rheumatoid pleuritis or empyema.

Ultrasound guidance for thoracentesis reduces complications (pneumothorax, hemothorax) and is the standard of care. Real-time ultrasound guidance is preferred over landmark-based technique, particularly for small or loculated effusions.

Parapneumonic effusion — pleural fluid accumulation in the setting of pneumonia — occurs in approximately 40% of bacterial pneumonias. The clinical course progresses through three stages: exudative (simple parapneumonic effusion, responds to antibiotics alone), fibrinopurulent (complicated parapneumonic effusion, requires drainage), and organizing (empyema with fibrous peel, may require surgical decortication).

The decision to drain is based on pleural fluid analysis and clinical context. Drainage is required when: pH is below 7.2, glucose is below 60 mg/dL, LDH is above 1000 IU/L, Gram stain or culture is positive, or frank pus is present (empyema). A simple parapneumonic effusion (pH above 7.2, glucose normal, sterile) can be managed with antibiotics alone and close monitoring.

Drainage options depend on the complexity of the effusion. A free-flowing effusion can be drained by thoracentesis or chest tube. A loculated effusion may require image-guided chest tube placement, intrapleural fibrinolytics (tPA + DNase), or VATS. The choice depends on the extent of loculation, the patient's clinical status, and institutional expertise.

Failure to drain a complicated parapneumonic effusion is a common cause of apparent antibiotic treatment failure in pneumonia. A patient with pneumonia who is not improving despite appropriate antibiotics should have imaging to evaluate for a parapneumonic effusion — and if present, thoracentesis with fluid analysis is essential.

Malignant pleural effusions are exudates, often bloody, and frequently large and recurrent. They occur in approximately 15% of cancer patients and are most commonly associated with lung cancer, breast cancer, lymphoma, and mesothelioma. The presence of a malignant effusion generally indicates advanced disease and affects prognosis.

Cytology has a sensitivity of approximately 60% for malignancy — a negative cytology does not exclude malignant effusion. Repeat thoracentesis with cytology increases the yield to approximately 70–80%. Pleural biopsy (CT-guided or thoracoscopic) is needed when cytology is negative but malignancy is strongly suspected.

Management of recurrent malignant effusions focuses on symptom relief and preventing re-accumulation. Options include: repeated therapeutic thoracentesis (for patients with limited life expectancy or poor performance status), indwelling pleural catheter (IPC — allows outpatient drainage and is preferred for most patients with recurrent malignant effusion), and pleurodesis (chemical or mechanical obliteration of the pleural space — requires lung re-expansion and is less effective when the lung is trapped).

Indwelling pleural catheters have become the preferred approach for most patients with recurrent malignant effusions — they allow outpatient management, reduce hospitalizations, and provide equivalent symptom relief compared to pleurodesis. Spontaneous pleurodesis occurs in approximately 40–50% of patients with IPCs, potentially allowing catheter removal.

Transudative effusions are managed by treating the underlying cause. Heart failure effusions respond to diuresis — thoracentesis is not required unless the effusion is causing significant symptoms or the diagnosis is uncertain. Hepatic hydrothorax (from cirrhosis) is managed with sodium restriction and diuretics; refractory cases may require TIPS or liver transplant evaluation. Hypoalbuminemia-associated effusions require addressing the underlying protein deficit.

Exudative effusions require identification of the specific cause before management can be directed. Parapneumonic effusions: uncomplicated parapneumonic effusions (pH above 7.2, glucose above 60, LDH below 1000, no organisms on Gram stain or culture) can be managed with antibiotics alone. Complicated parapneumonic effusions (pH below 7.2, glucose below 60, positive Gram stain or culture) and empyema require drainage — typically with a chest tube. Fibrinolytics (tPA/DNase) instilled through the chest tube can improve drainage in loculated empyema.

Tuberculous effusions: treat with standard anti-tuberculous therapy. Thoracentesis for diagnosis and symptom relief; drainage is not required for most TB effusions. Corticosteroids may reduce the risk of pleural thickening in some patients.

Expected course: transudative effusions resolve with treatment of the underlying cause. Parapneumonic effusions that are drained appropriately resolve over weeks. Malignant effusions recur in most patients — management shifts to palliation and symptom control. Residual pleural thickening after effusion resolution is common and does not require treatment unless it causes restrictive physiology.

When to escalate: effusions causing hemodynamic compromise (tension hydrothorax — rare), bilateral effusions without a clear cause, suspected empyema, effusions in immunocompromised patients, and any effusion where the diagnosis remains uncertain after initial evaluation warrant pulmonology or thoracic surgery consultation.